Recent Updates
Recently added Catalysts

Plasma-Lyte 148 Infusion

Phase 3

End Stage Kidney Disease | Small molecule | Nephrology |Baxter International Inc.|Last Updated: Oct 15, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment808
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03829488Better Evidence for Selecting Transplant FluidsPHASE3 COMPLETED 808Jan 26, 2018May 3, 2022Oct 15, 202418 Australia, New Zealand
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
The proportion of participants with Delayed Graft Function
7 Days

Delayed Graft Function defined as receiving treatment with any form of dialysis in the first seven days after transplant

Secondary Endpoints
Early Kidney Transplant Function
a. Duration of Delayed Graft Function - 12 Weeks; b. Rate of recovery of kidney transplant graft function - 2 Days
Number of dialysis sessions
First 28 days post-transplant
Total duration of dialysis
12 Weeks
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Plasma-Lyte 148 (approx. pH 7.4) IV InfusionEXPERIMENTALPlasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
0.9% SODIUM CHLORIDE 9g/L injection BPACTIVE_COMPARATOR0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
Interventions
NameTypeDescription
Plasma-Lyte 148 (approx. pH 7.4) IV InfusionDRUGPlasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
0.9% SODIUM CHLORIDE 9g/L injection BPDRUGSodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
Unlock Study Design Details
Eligibility Criteria
SexALL
Healthy VolunteersNo
Study Sites18

Inclusion Criteria: 1. Adult or child with End-Stage Kidney Disease, of any cause, on maintenance dialysis, or who has pre-dialysis stage 5 chronic kidney disease with an estimated Glomerular Filtration Rate of \<15 mL/min/1.73m2, AND 2. Planned deceased donor kidney transplant from a brain-death (...

Countries:AustraliaNew Zealand
Unlock Eligibility Criteria